Bortezomib CAS 179324-69-7 Anticancer Raw Materials Powder

CAS: 179324-69-7

MF: C19H25BN4O4

MW: 384.24

EINECS: 605-854-3

Specification​: 99% min Bortezomib

Sample: Bortezomib Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Bortezomib Powder Usage and Synthesis.

Bortezomib Powder, a novel targeted drug for myeloma, received widespread attention from the pharmaceutical industry for its discovery and was awarded the 2004 Nobel Prize in Chemistry for its mechanism of action. In 2006, Bortezomib CAS 179324-69-7 was awarded the PrixGalien, the highest honor in the In 2006, Bortezomib CAS 179324-69-7 was awarded the PrixGalien, the highest honor in the pharmaceutical industry, as "a revolution in oncology treatment and a major advance in the treatment of multiple myeloma". Several international clinical studies have demonstrated that regimens containing Bortezomib Raw Materials are significantly more effective than Several international clinical studies have demonstrated that regimens containing Bortezomib Raw Materials are significantly more effective than traditional chemotherapy regimens, significantly increasing the rate of complete remission, prolonging patient survival and improving quality of Bortezomib has also become the first-line treatment of choice for myeloma as it is used throughout the induction, consolidation, and maintenance Bortezomib is a new and innovative treatment for myeloma.

Application/Function of Bortezomib Powder.

Before the introduction of bortezomib, multiple myeloma was a nightmare for patients with this type of disease. The advantages of bortezomib as a breakthrough drug for myeloma are mainly in the following aspects:

• 1. fast onset of action, taking only about 1 month to take effect;
• 2. significant efficacy, with remission rates of more than 80% and complete remission rates to 30%-40% with the combination of drugs. SWOS0777 study published in The Lancet in 2017 showed that the bortezomib combined with lenalidomide and dexamethasone (BRD) regimen prolonged the median survival of patients by 11 months compared with the lenalidomide combined with dexamethasone (RD) regimen, and the median survival of patients in the BRD regimen group reached 75 months;
• 3. a high safety profile, which can be applied to patients suffering from renal insufficiency or even renal failure, with efficacy comparable to that of patients with normal renal function, and the ability to reverse renal function;
• 4. Bortezomib-based induction therapy can significantly increase the amount of stem cells collected and significantly accelerate the speed of stem cell collection.

Several international clinical studies have demonstrated that regimens containing bortezomib are significantly more effective than traditional chemotherapy regimens, significantly increasing the rate of complete remission, prolonging patient survival, and improving the quality of survival. Bortezomib has become the first-line treatment of choice for myeloma as it is administered throughout the induction, consolidation and maintenance phases of treatment.

Bortezomib is the first proteasome inhibitor approved by the U.S. FDA for multiple myeloma, a blood cancer. The reversible 26S proteasome inhibitor, a barrel-shaped multiprotein particle, is present in the nucleus and cytoplasm of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.

Production Method of Bortezomib Powder

Bortezomib is a white or off-white crystalline powder, soluble in dimethyl sulfoxide, ethanol and insoluble in aqueous solution, and is a reversible inhibitor of chymotrypsin-like activity of the 26S proteasome, a large protein complex that degrades pan-proteins in mammalian cells. Pan-proteasome channels play an important role in regulating the intracellular concentration of specific proteins to maintain the stability of the intracellular environment. Protein hydrolysis affects intracellular multilevel signaling crosstalk, and this disruption of the normal intracellular environment can lead to cell death.

Inhibition of the 26S proteasome prevents the hydrolysis of specific proteins. In vitro tests have demonstrated the cytotoxic effects of bortezomib on several types of cancer cells. In vivo trials in preclinical tumor models have demonstrated that bortezomib delays the growth of tumors, including multiple myeloma, and is indicated for the treatment of those with multiple myeloma.

It is a diamine oxidase inhibitor, which has significant dilating effects on cardiovascular and cerebral vessels, especially on the vertebral artery system, significantly increasing blood flow in the heart, brain and peripheral circulation, improving blood circulation, and lowering systemic blood pressure, in addition to increasing cochlear and vestibular blood flow, thereby eliminating inner ear vertigo, tinnitus and aural closure, as well as increasing capillary permeability, promoting the absorption of extracellular fluid, and eliminating intra-lymphoedema It also increases capillary permeability, promotes extracellular fluid absorption and eliminates intra-lymphatic edema;

It can counteract the vasoconstrictive effect of catecholamines and lower arterial pressure, and inhibit plasma coagulation and ADP-induced platelet agglutination, prolong the time of thrombosis in vitro in rats, and have a slight diuretic effect.

• 1、Multiple myeloma: This product can be used in combination with melphalan and prednisone (MP regimen) for the treatment of previously untreated multiple myeloma patients who are not suitable for high-dose chemotherapy and myelosuppression; or used alone for the treatment of multiple myeloma patients who have relapsed after receiving at least one or more kinds of treatment.
• 2. SLE: This product may be used for the treatment of patients with relapsed or refractory sleeve cell lymphoma who have received at least one therapy prior to the use of this product. Safety and efficacy data for this indication were obtained from a single-arm phase II clinical study (see Clinical Trials) in a foreign country for relapsed lymphoma after previous treatment.